{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:24:16Z","timestamp":1793017456905,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>\n                      Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) caused by a somatic gain-of-function mutation of the\n                      <jats:italic>Janus kinase2<\/jats:italic>\n                      (\n                      <jats:italic>JAK2)<\/jats:italic>\n                      gene in hematopoietic stem and peripheral blood cells, leading to erythrocytosis which is often accompanied by leukocytosis and thrombocytosis. Historically, PV management has mainly focused on maintaining hematocrit (HCT) levels below 45% to reduce major thrombotic risk, improving symptoms and monitoring disease progression. Phlebotomy alone or in combination with cytoreductive therapy, where indicated, form the current standard of care. This review explores the potential correlation between the depletion of neoplastic clones in patients with PV with the achievement of durable complete molecular remission (CMR), and long-term treatment effects on thrombotic events and survival, as well as implications for re-defining treatment goals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\u00a0Recent Findings<\/jats:title>\n                    <jats:p>\n                      Past management practices do not ideally optimize outcomes for patients with PV. Specifically, these approaches do not adequately address the underlying risk of disease progression driven by the neoplastic cells carrying mutated\n                      <jats:italic>JAK2<\/jats:italic>\n                      and additional mutations.\n                    <\/jats:p>\n                    <jats:p>\n                      Patients with PV who are treated with interferon-based therapies can achieve complete hematologic response, together with a significant reduction of\n                      <jats:italic>JAK2<\/jats:italic>\n                      V617F Variant Allele Frequency (VAF). Continued reduction of the\n                      <jats:italic>JAK2<\/jats:italic>\n                      VAF may lead to CMR and is correlated with in vivo drug exposures and durable improvement of thrombotic risk, as well as increased probability of event-free survival (EFS). The results indicate that reduction in\n                      <jats:italic>JAK2<\/jats:italic>\n                      V617F VAF, and by extension depletion of neoplastic cells, is essential for favorable long term clinical outcomes in patients with PV.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>\n                      Emerging data suggest a direct correlation between deep reduction in\n                      <jats:italic>JAK2<\/jats:italic>\n                      V617F VAF as a measure of suppressing neoplastic cells and improved probability of EFS and delayed disease progression. These observations suggest a treatment paradigm shift from solely managing symptoms and preventing thrombotic events, toward achieving durable clonal depletion with potential for remission and preventing transformation to myelofibrosis or acute myeloid leukemia.\n                    <\/jats:p>\n                    <jats:p>Integration of molecular biomarkers into risk-adapted treatment algorithms may enable personalized approaches to achieve deep molecular responses and durable disease modification in PV. Clonal molecular response, therefore, deserves attention as a biomarker of response that should be evaluated in clinical trials, as well as for treatment monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11899-025-00758-x","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T03:11:02Z","timestamp":1759893062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera"],"prefix":"10.1007","volume":"20","author":[{"given":"Minghui","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"4","key":"758_CR1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ejh.12256","volume":"92","author":"O Moulard","year":"2014","unstructured":"Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92(4):289\u201397.","journal-title":"Eur J Haematol"},{"issue":"12","key":"758_CR2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599\u2013613.","journal-title":"Am J Hematol"},{"issue":"1","key":"758_CR3","first-page":"92","volume":"16","author":"FA Khan","year":"2012","unstructured":"Khan FA, Khan RA, Iqbal M, Hussain S, Anaesth. Pain Intensive Care. 2012;16(1):92\u20138.","journal-title":"Pain Intensive Care"},{"issue":"1","key":"758_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"758_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41572-025-00608-3","volume":"11","author":"CN Harrison","year":"2025","unstructured":"Harrison CN, Barbui T, Bose P, Kiladjian JJ, Mascarenhas J, McMullin MF, et al. Polycythaemia vera. Nat Rev Dis Primers. 2025;11(1):26.","journal-title":"Nat Rev Dis Primers"},{"issue":"19","key":"758_CR6","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Elisa Rumiet E, et al. In contemporary patients with polycythemia vera, rate of thrombosis is lower than historically reported. Blood. 2014;124(19):3021\u20133.","journal-title":"Blood"},{"key":"758_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"758_CR8","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5(11):e366.","journal-title":"Blood Cancer J"},{"issue":"12","key":"758_CR9","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","volume":"35","author":"A Tefferi","year":"2021","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021;35(12):3339\u201351.","journal-title":"Leukemia"},{"issue":"9","key":"758_CR10","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874\u201381.","journal-title":"Leukemia"},{"issue":"10","key":"758_CR11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","volume":"117","author":"F Passamonti","year":"2004","unstructured":"Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755\u201361.","journal-title":"Am J Med"},{"issue":"4","key":"758_CR12","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Maria A, Vannucchi, et al. Appropriate management of polycythaemia Vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9(4):e301\u201311.","journal-title":"Lancet Haematol"},{"key":"758_CR13","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms, version 1.2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1477"},{"issue":"2","key":"758_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114\u201324.","journal-title":"N Engl J Med"},{"key":"758_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2204621","author":"RMF Randrianarisoa","year":"2023","unstructured":"Randrianarisoa RMF, Ramanandafy H, Mania A, Monjanel H, Trouillier S. Prevalence and diagnostic performance of iron deficiency in polycythemia. Hematology. 2023. https:\/\/doi.org\/10.1080\/16078454.2023.2204621.","journal-title":"Hematology"},{"issue":"8","key":"758_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.clml.2024.04.003","volume":"24","author":"AT Kuykendall","year":"2024","unstructured":"Kuykendall AT, Fine JT, Kremyanskaya M. Contemporary challenges in polycythemia vera management from the perspective of patients and physicians. Clin Lymphoma Myeloma Leuk. 2024;24(8):512\u201322.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"758_CR17","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00277-022-04963-z","volume":"101","author":"A Triguero","year":"2022","unstructured":"Triguero A, Pedraza A, P\u00e9rez-Encinas M, et al. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish registry of polycythemia vera. Ann Hematol. 2022;101(10):2231\u20139.","journal-title":"Ann Hematol"},{"issue":"6","key":"758_CR18","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T, European collaboration on Low-Dose aspirin in polycythemia Vera (ECLAP), et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446\u201352.","journal-title":"Blood"},{"issue":"2","key":"758_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.21593","volume":"85","author":"V De Stefano","year":"2010","unstructured":"De Stefano V, Za T, Rossi E, et al. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol. 2010;85(2):97\u2013100.","journal-title":"Am J Hematol"},{"issue":"3","key":"758_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","volume":"138","author":"N Gangat","year":"2007","unstructured":"Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138(3):354\u20138.","journal-title":"Br J Haematol"},{"issue":"16","key":"758_CR21","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood.2023020232","volume":"143","author":"T Gerds","year":"2024","unstructured":"Gerds T, Mesa A, Burke RM. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analyses from the REVEAL study. Blood. 2024;143(16):1646\u201355.","journal-title":"Blood"},{"issue":"3 Suppl 10","key":"758_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/sonc.2002.33756","volume":"29","author":"TC Pearson","year":"2002","unstructured":"Pearson TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin Oncol. 2002;29(3 Suppl 10):16\u201321.","journal-title":"Semin Oncol"},{"key":"758_CR23","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s00277-024-05809-6","volume":"103","author":"F Palandri","year":"2024","unstructured":"Palandri F, Branzanti F, Venturi M, et al. Real-life use of ropeg-interferon \u03b12b in polycythemia vera: patient selection and clinical outcomes. Ann Hematol. 2024;103:2347\u201354.","journal-title":"Ann Hematol"},{"issue":"19","key":"758_CR24","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","volume":"139","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Kosiorek E, Prchal H. A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022;139(19):2931\u201341.","journal-title":"Blood"},{"issue":"3","key":"758_CR25","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia Vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196\u2013208.","journal-title":"Lancet Haematol"},{"issue":"16","key":"758_CR26","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507\u201313.","journal-title":"Blood"},{"issue":"7","key":"758_CR27","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1182\/bloodadvances.2021004856","volume":"6","author":"TA Knudsen","year":"2022","unstructured":"Knudsen TA, Skov V, Stevenson K, et al. Genomic profiling of a randomized trial of interferon-\u03b1 vs hydroxyurea in MPN reveals mutation-specific responses. Blood Adv. 2022;6(7):2107\u201319.","journal-title":"Blood Adv"},{"issue":"5","key":"758_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13043","volume":"32","author":"C Cantisani","year":"2019","unstructured":"Cantisani C, Kiss N, Naqeshbandi AF, et al. Nonmelanoma skin cancer associated with hydroxyurea treatment: overview of the literature and our own experience. Dermatol Ther. 2019;32(5):e13043.","journal-title":"Dermatol Ther"},{"key":"758_CR29","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.3324\/haematol.2019.221234","volume":"104","author":"A Ferrari","year":"2019","unstructured":"Ferrari A, Carobbio A, Masciulli A, et al. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica. 2019;104:2391\u20139.","journal-title":"Haematologica"},{"issue":"29","key":"758_CR30","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","volume":"29","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29(29):3907\u201313.","journal-title":"J Clin Oncol"},{"issue":"17","key":"758_CR31","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29(17):2410\u20135.","journal-title":"J Clin Oncol"},{"key":"758_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1173467","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A. An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1. Front Oncol. 2023;13:1173467.","journal-title":"Front Oncol"},{"issue":"24","key":"758_CR33","doi-asserted-by":"publisher","first-page":"14411","DOI":"10.1073\/pnas.95.24.14411","volume":"95","author":"XQ Qin","year":"1998","unstructured":"Qin XQ, Tao N, Dergay A, et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA. 1998;95(24):14411\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"758_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/hum.2023.028","volume":"34","author":"A Qin","year":"2023","unstructured":"Qin A. A favorable benefit-risk balance maybe expected with replication-defective adenovirus-mediated interferon gene therapy for cancer treatment. Hum Gene Ther. 2023;34:339\u201340.","journal-title":"Hum Gene Ther"},{"issue":"6","key":"758_CR35","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","volume":"35","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf JP, Giri S, Wang R, et al. Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. Leukemia. 2021;35(6):1643\u201360.","journal-title":"Leukemia"},{"key":"758_CR36","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","volume":"37","author":"H Gisslinger","year":"2023","unstructured":"Gisslinger H, Klade C, Georgiev P, et al. Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia. 2023;37:2129\u201332.","journal-title":"Leukemia"},{"key":"758_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1109866","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A, Urbanski RW, Yu L, Ahmed T, Mascarenhas J. An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: an overview of previous and ongoing studies with perspectives on the future. Front Oncol. 2023;13:1109866.","journal-title":"Front Oncol"},{"issue":"1","key":"758_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40164-023-00415-0","volume":"12","author":"J Jin","year":"2023","unstructured":"Jin J, Zhang L, Qin A, et al. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Exp Hematol Oncol. 2023;12(1):55.","journal-title":"Exp Hematol Oncol"},{"issue":"1\u20132","key":"758_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14740\/jh1245","volume":"13","author":"SS Suo","year":"2024","unstructured":"Suo SS, Fu RF, Qin A, Shao ZH, Bai J, Chen SN, et al. Effective management of polycythemia Vera with ropeginterferon alfa-2b. J Hematol. 2024;13(1\u20132):12\u201322.","journal-title":"J Hematol"},{"issue":"6","key":"758_CR40","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1111\/bjh.19846","volume":"205","author":"S Suo","year":"2024","unstructured":"Suo S, Fu RF, Qin A, et al. Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b. Br J Haematol. 2024;205(6):2510\u20134.","journal-title":"Br J Haematol"},{"issue":"3","key":"758_CR41","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","volume":"8","author":"T Barbui","year":"2021","unstructured":"Barbui T, Maria Vannucchi A, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia Vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):e175\u201384.","journal-title":"Lancet Haematol"},{"issue":"5","key":"758_CR42","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P, et al. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia. 2022;36(5):1408\u201311.","journal-title":"Leukemia"},{"issue":"2","key":"758_CR43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12185-022-03341-9","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y, Ohishi K, Gotoh A, et al. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol. 2022;116(2):215\u201327.","journal-title":"Int J Hematol"},{"issue":"2","key":"758_CR44","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00277-023-05577-9","volume":"103","author":"T Barbui","year":"2024","unstructured":"Barbui T, Carobbio A, De Stefano V, et al. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes. Ann Hematol. 2024;103(2):437\u201342.","journal-title":"Ann Hematol"},{"issue":"6","key":"758_CR45","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12185-024-03846-5","volume":"120","author":"K Kirito","year":"2024","unstructured":"Kirito K, Sugimoto Y, Gotoh A, et al. Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera. Int J Hematol. 2024;120(6):675\u201383.","journal-title":"Int J Hematol"},{"key":"758_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35411","author":"SY Yoon","year":"2025","unstructured":"Yoon SY, Yoon SS, Yang DH, et al. Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study. Int J Cancer. 2025. https:\/\/doi.org\/10.1002\/ijc.35411.","journal-title":"Int J Cancer"},{"key":"758_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1586839","volume":"15","author":"L Chang","year":"2025","unstructured":"Chang L, Li WX, Cai H, et al. Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study. Front Oncol. 2025;15:1586839.","journal-title":"Front Oncol"},{"key":"758_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1089\/jir.1997.17.355","volume":"17","author":"XQ Qin","year":"1997","unstructured":"Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J. Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interf Cytokine Res. 1997;17:355\u201367.","journal-title":"J Interf Cytokine Res"},{"key":"758_CR49","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1089\/10799900260442511","volume":"22","author":"C Kaynor","year":"2002","unstructured":"Kaynor C, Xin M, Wakefield J, Barsoum J, Qin XQ. Direct evidence that IFN-beta functions as a tumor-suppressor protein. J Interferon Cytokine Res. 2002;22:1089\u201398.","journal-title":"J Interferon Cytokine Res"},{"key":"758_CR50","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1006\/mthe.2001.0464","volume":"4","author":"XQ Qin","year":"2001","unstructured":"Qin XQ, Beckham C, Brown JL, Lukashev M, Barsoum J. Human and mouse IFN-\u03b2 gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol Ther. 2001;4:356\u201364.","journal-title":"Mol Ther"},{"key":"758_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1089\/10799900260100222","volume":"22","author":"JL Brown","year":"2002","unstructured":"Brown JL, Barsoum J, Qin XQ. CD4\u2009+\u2009T helper cell-independent antitumor response mediated by murine IFN-beta gene delivery in immunocompetent mice. J Interferon Cytokine Res. 2002;22:719\u201328.","journal-title":"J Interferon Cytokine Res"},{"key":"758_CR52","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1080\/14796694.2024.2402649","volume":"20","author":"A Qin","year":"2024","unstructured":"Qin A. A plain Language summary about a cell cycle-based, new surveillance mechanism against cancer. Future Oncol. 2024;20:3209\u201312.","journal-title":"Future Oncol"},{"key":"758_CR53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.clinthera.2024.03.005","volume":"46","author":"A Qin","year":"2024","unstructured":"Qin A. Mechanism of action of ropeginterferon alfa-2b in polycythemia vera treatment. Clin Ther. 2024;46:439\u201340.","journal-title":"Clin Ther"},{"issue":"16","key":"758_CR54","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1182\/blood.2022017697","volume":"141","author":"AR Moliterno","year":"2023","unstructured":"Moliterno AR, Kaizer H, Reeves BN. JAK2V617F allele burden in polycythemia vera: burden of proof. Blood. 2023;141(16):1934\u201342.","journal-title":"Blood"},{"issue":"6","key":"758_CR55","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1002\/cam4.2886","volume":"9","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhou Y, Wang Y, et al. Thrombosis among 1537 patients with JAK2V617F-mutated myeloproliferative neoplasms: risk factors and development of a predictive model. Cancer Med. 2020;9(6):2096\u2013105.","journal-title":"Cancer Med"},{"key":"758_CR56","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24:1574\u20139.","journal-title":"Leukemia"},{"issue":"12","key":"758_CR57","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","volume":"11","author":"P Guglielmelli","year":"2021","unstructured":"Guglielmelli P, Loscocco GG, Mannarelli C, et al. JAK2V617F variant allele frequency\u2009>\u200950% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. 2021;11(12):199.","journal-title":"Blood Cancer J"},{"issue":"19","key":"758_CR58","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/JCO.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41(19):3534\u201344.","journal-title":"J Clin Oncol"},{"issue":"11","key":"758_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks203","volume":"40","author":"AS Whale","year":"2012","unstructured":"Whale AS, Huggett JF, Cowen S, et al. Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res. 2012;40(11):e82.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"758_CR60","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1128\/JCM.02620-12","volume":"51","author":"RT Hayden","year":"2013","unstructured":"Hayden RT, Gu Z, Ingersoll J, et al. Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus. J Clin Microbiol. 2013;51(2):540\u20136.","journal-title":"J Clin Microbiol"},{"issue":"Suppl 1","key":"758_CR61","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1182\/blood-2021-147061","volume":"138","author":"G Abu-Zeinah","year":"2021","unstructured":"Abu-Zeinah G, Richard T, Silver, et al. Normal life expectancy for polycythemia Vera patients is possible. Blood. 2021;138(Suppl 1):2575.","journal-title":"Blood"},{"issue":"9","key":"758_CR62","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","volume":"35","author":"G Abu-Zeinah","year":"2021","unstructured":"Abu-Zeinah G, Krichevsky S, Cruz T, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;35(9):2592\u2013601.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"758_CR63","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2023-173127","volume":"142","author":"TA Knudsen","year":"2023","unstructured":"Knudsen TA, Hansen DL, Ocias LF, et al. Final analysis of the Daliah trial: a randomized phase III trial of Interferon-\u03b1 versus hydroxyurea in patients with MPN. Blood. 2023;142(Suppl 1):746.","journal-title":"Blood"},{"issue":"Suppl 1","key":"758_CR64","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-141223","volume":"136","author":"RD De Oliveira","year":"2020","unstructured":"De Oliveira RD, Soret-Dulphy J, Zhao L-P, et al. Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission. Blood. 2020;136(Suppl 1):35\u20136.","journal-title":"Blood"},{"key":"758_CR65","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/bcp.16043","volume":"90","author":"A Qin","year":"2024","unstructured":"Qin A, Wu D, Li Y, et al. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera. Br J Clin Pharmacol. 2024;90:1493\u2013502.","journal-title":"Br J Clin Pharmacol"},{"key":"758_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70109","volume":"13","author":"A Qin","year":"2025","unstructured":"Qin A, Shimoda K, Suo S, et al. Population pharmacokinetics-pharmacodynamics and exposure-response of ropeginterferon alfa-2b in Chinese and Japanese patients with polycythemia vera. Pharmacol Res Perspect. 2025;13:e70109.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"758_CR67","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","volume":"4","author":"LP Masarova","year":"2017","unstructured":"Masarova LP, Patel K, Newberry KJ, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017;4(4):e165\u201375.","journal-title":"Lancet Haematol"},{"key":"758_CR68","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/10428199909145955","volume":"36","author":"M Bentley","year":"1999","unstructured":"Bentley M, Taylor K, Grigg A, et al. Long-term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia. Leuk Lymphoma. 1999;36:123\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"758_CR69","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1182\/blood-2018-99-111255","volume":"132","author":"TA Knudsen","year":"2018","unstructured":"Knudsen TA, Hansen DL, Ocias LF, et al. Long-term efficacy and safety of recombinant interferon alpha-2 vs. hydroxyurea in polycythemia vera: preliminary results from the three-year analysis of the DALIAH trial\u2014a randomized controlled phase III clinical trial. Blood. 2018;132(Suppl 1):580.","journal-title":"Blood"},{"issue":"12","key":"758_CR70","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GKK, Bonino F, et al. Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12):1206\u201317.","journal-title":"N Engl J Med"},{"key":"758_CR71","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s12072-020-10098-y","volume":"14","author":"YW Huang","year":"2020","unstructured":"Huang YW, Hsu CW, Lu SN, et al. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. Hepatol Int. 2020;14:997\u20131008.","journal-title":"Hepatol Int"},{"key":"758_CR72","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s12072-025-10824-4","volume":"19","author":"A Qin","year":"2025","unstructured":"Qin A, Ho MC, Tsai CY, et al. Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial. Hepatol Int. 2025;19:547\u201359.","journal-title":"Hepatol Int"},{"key":"758_CR73","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426\u201335.","journal-title":"N Engl J Med"},{"issue":"1","key":"758_CR74","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjh.14382","volume":"176","author":"R Mesa","year":"2017","unstructured":"Mesa R, Vannucchi AM, Yacoub A, et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol. 2017;176(1):76\u201385.","journal-title":"Br J Haematol"},{"key":"758_CR75","unstructured":"JAKAFI US Prescribing Informationhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202192s015lbl.pdf. https:\/\/www.jakafi.com\/jakafi-prescribing-information"},{"issue":"7","key":"758_CR76","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","volume":"9","author":"F Passamonti","year":"2022","unstructured":"Passamonti F, Palandri F, Saydam G, et al. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia Vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet Haematol. 2022;9(7):e480\u201392.","journal-title":"Lancet Haematol"},{"issue":"20","key":"758_CR77","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1182\/bloodadvances.2024013170","volume":"8","author":"AL S\u00f8rensen","year":"2024","unstructured":"S\u00f8rensen AL, Skov V, Kj\u00e6r L, et al. Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera. Blood Adv. 2024;8(20):5416\u201325.","journal-title":"Blood Adv"},{"issue":"12","key":"758_CR78","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1080\/13543784.2016.1250882","volume":"25","author":"P Bose","year":"2016","unstructured":"Bose P, Verstovsek S. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs. 2016;25(12):1393\u2013403.","journal-title":"Expert Opin Investig Drugs"},{"issue":"22","key":"758_CR79","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2023021503","volume":"142","author":"JP Bewersdorf","year":"2023","unstructured":"Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, et al. Moving toward disease modification in polycythemia vera. Blood. 2023;142(22):1859\u201370.","journal-title":"Blood"},{"issue":"18","key":"758_CR80","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1182\/blood.2020009138","volume":"137","author":"W Chen","year":"2021","unstructured":"Chen W, Hill H, Christie A, et al. Therapeutic Inhibition of HIF-2\u03b1 reverses polycythemia and pulmonary hypertension in preclinical models. Blood. 2021;137(18):2509\u201319.","journal-title":"Blood"},{"issue":"Suppl 1","key":"758_CR81","doi-asserted-by":"publisher","first-page":"6722","DOI":"10.1182\/blood-2022-162621","volume":"140","author":"S Rai","year":"2022","unstructured":"Rai S, Stetka J, Usart M, et al. The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs). Blood. 2022;140(Suppl 1):6722\u20133.","journal-title":"Blood"},{"issue":"5","key":"758_CR82","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/2643-3230.BCD-22-0189","volume":"4","author":"PC Nair","year":"2023","unstructured":"Nair PC, Piehler J, Tvorogov D, Ross DM, Lopez AF, Gotlib J, et al. Next-generation JAK2 inhibitors for the treatment of myeloproliferative neoplasms: lessons from structure-based drug discovery approaches. Blood Cancer Discov. 2023;4(5):352\u201364.","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"758_CR83","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.stem.2021.02.001","volume":"28","author":"D Van Egeren","year":"2021","unstructured":"Van Egeren D, Escabi J, Nguyen M, et al. Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms. Cell Stem Cell. 2021;28(3):514\u2013e5239.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"758_CR84","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13256-016-1028-y","volume":"10","author":"G Gill","year":"2016","unstructured":"Gill G, Bajwa H, Strouhal P, et al. Interaction of interferon alpha therapy with thyroid function tests in the management of hepatitis C: a case report. J Med Case Rep. 2016;10(1):253.","journal-title":"J Med Case Rep"},{"issue":"3","key":"758_CR85","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2249.1992.tb05852.x","volume":"90","author":"H Gisslinger","year":"1992","unstructured":"Gisslinger H, Gilly B, Woloszczuk W, et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol. 1992;90(3):363\u20137.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"758_CR86","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.pnpbp.2005.03.006","volume":"29","author":"GM Asnis","year":"2005","unstructured":"Asnis GM, De La Garza R. Interferon-induced depression: strategies in treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(5):808\u201318.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"24","key":"758_CR87","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.3390\/cells11244041","volume":"11","author":"LY Huang","year":"2022","unstructured":"Huang LY, Chiu CJ, Hsing CH, Hsu YH. Interferon family cytokines in obesity and insulin sensitivity. Cells. 2022;11(24):4041.","journal-title":"Cells"},{"issue":"9","key":"758_CR88","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","volume":"37","author":"T Stauffer Larsen","year":"2013","unstructured":"Stauffer Larsen T, Iversen KK, Hansen E, et al. Long-term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia Vera and myelofibrosis treated with Recombinant interferon alpha. Leuk Res. 2013;37(9):1041\u20135.","journal-title":"Leuk Res"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00758-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00758-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00758-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:03:46Z","timestamp":1769051026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00758-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["758"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00758-x","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Minghui Duan: no competing interests to declare.Prithviraj Bose: Grants (Incyte, CTI (now Sobi), MorphoSys (now Novartis), Kartos, Telios, Ionis, Disc, Blueprint, Cogent, Geron, Janssen, Sumitomo, BMS, Karyopharm, Ajax); consulting fees (Incyte, BMS, CTI (now Sobi), GSK, AbbVie, MorphoSys (now Novartis), Karyopharm, PharmaEssentia, Blueprint, Cogent, Novartis, Jubilant, Morphic, Ono, Sumitomo, Keros (now Takeda), Takeda, Raythera, Ionis, Disc, Geron); honoraria for lectures\/advisory boards (Incyte, Blueprint, GSK, CTI, AbbVie, Sumitomo, PharmaEssentia).Zhijian Xiao: no competing interests to declare.Anthony M Hunter: has received honoraria\/consulting fees from GSK, Cogent Biosciences, PharmaEssentia, Blueprint Medicines, CTI Biopharma (now Sobi) and Incyte; declares research funding from Incyte, Cogent Biosciences, Ascentage Pharma, Blueprint Medicines, Syntrix Biosystems, Novartis, Shenzen TargetRx, and PharmaEssentia.Albert Qin: serving as the chief medical officer of PharmaEssentia Corporation.Long Chang: no competing interests to declare.Wenxin Li: no competing interests to declare.Daoxiang Wu: employed by PharmaEssentia Biotech Ltd (Beijing).Raajit K. Rampal: Grants (Incyte, Ryvu, MorphoSys, Zentalis); consulting fees (MorphoSys, CTI, GSK, Stemline, Blueprint, SDP, Servier, Zentalis, BMS, Galectco, AbbVie, PharmaEssentia, Cogent, Kartos); honoraria for lectures\/advisory boards (Protagonist, Karyopharm, GSK); monitoring or advisory board (Kartos).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13"}}